| Date | Title | | | December 30, 2016 | Incyte Announces First Patient Treated in Pivotal Clinical Trial Program for Ruxolitinib (Jakafi®) in Graft-versus-Host Disease| WILMINGTON, Del.--(BUSINESS WIRE)--Dec. 30, 2016--
Incyte Corporation (Nasdaq:INCY) today announced that the first patient
has been treated in the REACH-1 pivotal Phase 2 trial evaluating
ruxolitinib (Jakafi®) in combination with corticosteroids for
the treatment of patients with steroid-refractory acute
graft-versus-host disease (GVHD).
“We are very pleased to have the first patient treated in the pivotal
trial program for ruxolitinib in ... |
|  | | December 21, 2016 | Incyte and Merus Announce Global Strategic Research Collaboration to Discover and Develop Bispecific Antibodies| Collaboration designed to leverage Merus’ Biclonics®
bispecific antibody technology to expand Incyte’s discovery
capabilities and large-molecule portfolio
Incyte to make up-front payment of $120 million and purchase $80
million of Merus common shares; Merus eligible to receive potential
development, regulatory and commercial milestones and sales royalties
Merus conference call scheduled today at 8:30 a.m. ET, 2... |
| | | December 16, 2016 | CHMP Recommends Approval of Lilly's Baricitinib for the Treatment of Adults with Moderate to Severe Active Rheumatoid Arthritis (RA)| INDIANAPOLIS, Dec. 16, 2016 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Incyte Corporation (NASDAQ: INCY) announced today that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion, recommending the approval of baricitinib - which if approved would be marketed as Olumiant®. Baricitinib would be indicated for the treatment of moderate to severe active rheumatoid arthritis in adult patients who have responded inadequat... |
| | | December 13, 2016 | Incyte to Present at Upcoming Investor Conference| WILMINGTON, Del.--(BUSINESS WIRE)--Dec. 13, 2016--
Incyte Corporation (Nasdaq:INCY) announced today that it will present at
the 35th Annual J.P. Morgan Healthcare Conference on Monday,
January 9, 2017 at 1:30 pm (PST) in San Francisco.
The presentation and Q&A session will be webcast live and can be
accessed at www.incyte.com
in the Investors section under “Events and Presentations.” Investors
interested in listening to the live webcas... |
| | | December 04, 2016 | Pooled Analysis of Five-Year Data from Two Phase 3 Studies Further Supports Overall Survival Advantage Observed in Patients with Myelofibrosis Treated With Jakafi® (ruxolitinib)| - Long-term treatment with Jakafi prolonged survival compared to
controls
- Data suggest that earlier treatment with Jakafi may improve
survival advantage for patients with myelofibrosis (MF)
WILMINGTON, Del.--(BUSINESS WIRE)--Dec. 4, 2016--
Incyte Corporation (Nasdaq:INCY) today announces an exploratory pooled
analysis of data from the five-year follow-up of the Phase 3 COMFORT-I
and COMFORT-II trials which further supports previously... |
| | | November 14, 2016 | New Analyses of Phase 3 Trials Show Improvements in Rheumatoid Arthritis Symptoms Following Treatment with Baricitinib Across Diverse Population of Patients| Three post-hoc analyses of two phase 3 studies showed improvements in rheumatoid arthritis symptoms in patients irrespective of age, BMI and number of previously used conventional synthetic DMARDsINDIANAPOLIS, Nov. 14, 2016 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Incyte Corporation (NASDAQ: INCY) today announced new data analyses of two phase 3 trials, RA-BUILD and RA-BEAM, showing that baricitinib treatment resulted in improvements in rheumatoid arthritis (RA) symptoms across a di... |
| | | November 14, 2016 | Baricitinib Demonstrates Early Response Compared to Placebo and Significant Improvement Compared to Adalimumab in Patient-Reported Outcomes| - Significant improvement in joint pain, severity of morning joint stiffness and tiredness with baricitinib compared to placebo, were seen as early as day 3 - Post-hoc analysis of two phase 3 studies shows significantly improved joint pain, severity of morning joint stiffness and tiredness compared to adalimumab, within 3 weeks of treatment in patients with rheumatoid arthritis who had inadequate response to conventional synthetic DMARDs, including methotrexateINDIANAPOLIS, Nov. 14, 2016 /PRNews... |
| | | November 03, 2016 | More Than 20 Abstracts Highlighting Data from Incyte’s Portfolio Accepted for Presentation at the 58th Annual ASH Meeting| WILMINGTON, Del.--(BUSINESS WIRE)--Nov. 3, 2016--
Incyte Corporation (Nasdaq: INCY) announces that more than 20 abstracts
including data from its ongoing clinical development program for Jakafi®
(ruxolitinib) and its small molecule development programs targeting
JAK1, LSD1 and PI3Kδ will be presented at the upcoming American Society
of Hematology (ASH) Annual Meeting 2016 in San Diego, California from
December 3-6, 2016.
“We are pleased to... |
| | | November 02, 2016 | New data from pivotal RA-BEACON study show significant improvement in patient-reported outcomes in rheumatoid arthritis patients treated with baricitinib compared to placebo| Phase 3 trial results published in Annals of the Rheumatic Diseases demonstrate baricitinib's significant efficacy in patients with inadequate response to conventional and biologic DMARDs INDIANAPOLIS, Nov. 2, 2016 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Incyte Corporation (NASDAQ: INCY) announced today that new data from RA-BEACON - a pivotal phase 3 study of baricitinib in the treatment of moderate-to-severe rheumatoid arthritis (RA) - showed baricitinib demonstrated significant... |
| | | November 02, 2016 | Incyte to Present at Upcoming Investor Conference| WILMINGTON, Del.--(BUSINESS WIRE)--Nov. 2, 2016--
Incyte Corporation (Nasdaq:INCY) announced today that it will present at
the 28th Annual Piper Jaffray Healthcare Conference on
Tuesday, November 29, 2016 at 11:30 am (EST) in New York.
The presentation will be webcast live and can be accessed at www.incyte.com
in the Investors section under “Events and Presentations”. Investors
interested in listening to the live webcast should log on before the
... |
| | | November 01, 2016 | Incyte Reports 2016 Third-Quarter Financial Results and Updates Key Clinical Programs| $224 million of 2016 third-quarter net product revenues from Jakafi®
(ruxolitinib), representing 39 percent growth over the same period
last year
Jakafi included as a recommended treatment for patients with
myelofibrosis in the NCCN® Guidelines for
myeloproliferative neoplasms (MPNs)
Updated Phase 1 data from ECHO-202 reinforced durability of
anti-tumor response in patients with advanced or metastatic ... |
| | | October 14, 2016 | Incyte to Report Third Quarter Financial Results| WILMINGTON, Del.--(BUSINESS WIRE)--Oct. 14, 2016--
Incyte Corporation (Nasdaq: INCY) announced today that it has scheduled
its third quarter 2016 financial results conference call and webcast for
10:00 a.m. ET on Tuesday, November 1, 2016.
The schedule for the press release and conference call/webcast is as
follows:
•
... |
| | | October 07, 2016 | Additional Phase 1 Data from ECHO-202 Reinforce Durability of Response in Patients with Treatment-naive Advanced or Metastatic Melanoma Treated with Epacadostat in Combination with Keytruda® (pembrolizumab)| Updated data published at ESMO to be discussed on Incyte investor
conference call and webcast today, 7 October, at 14:00 CET / 8:00 a.m. ET
WILMINGTON, Del.--(BUSINESS WIRE)--Oct. 7, 2016--
Incyte Corporation (Nasdaq:INCY) today announced that updated data from
the Phase I portion of the ECHO-202 trial evaluating the safety and
efficacy of epacadostat, Incyte’s selective IDO1 enzyme inhibitor, in
combination with pembrolizumab (Keytruda®)*, Merck’s
... |
| | | September 28, 2016 | Updated Phase 1 Data Reinforce the Clinical Profile of Epacadostat in Combination with Keytruda® (Pembrolizumab)| Incyte’s IDO1 inhibitor in combination with Merck’s anti-PD-1 therapy
is well-tolerated and demonstrates durable clinical response in patients
with treatment-naïve advanced melanoma
WILMINGTON, Del.--(BUSINESS WIRE)--Sep. 28, 2016--
Incyte Corporation (Nasdaq: INCY) today announced that the European
Society for Medical Oncology (ESMO) has published an abstract (#1110PD)
containing updated data from the Phase 1 portion of the ECHO-202 trial
eva... |
| | | September 27, 2016 | NCCN Guidelines® Recommend Jakafi® (ruxolitinib) for the Treatment of Myelofibrosis| Treatment guidelines for myeloproliferative neoplasms (MPNs) focused
on the treatment of myelofibrosis (MF), a rare blood cancer, published
today
WILMINGTON, Del.--(BUSINESS WIRE)--Sep. 27, 2016--
Incyte Corporation (Nasdaq: INCY) today announced that its
first-in-class JAK1/JAK2 inhibitor, Jakafi® (ruxolitinib),
has been included as a recommended treatment in the latest National
Comprehensive Cancer Network® (NCCN®)
Clinical Practice G... |
| | | September 08, 2016 | Incyte Supports Those Affected by Rare Blood Cancers on MPN Awareness Day and Throughout Blood Cancer Awareness Month| MPN Landmark Survey Underscores Burden of Disease in MPN Patients and
the Importance of Raising Awareness Today and Throughout the Month of
September
WILMINGTON, Del.--(BUSINESS WIRE)--Sep. 8, 2016--
Incyte Corporation calls for increased awareness and support for those
living with myeloproliferative neoplasms (MPNs) today, MPN Awareness
Day, and throughout September, Blood Cancer Awareness Month. MPNs are a
closely related group of rare, prog... |
| | | August 30, 2016 | Incyte to Present at Upcoming Investor Conferences| WILMINGTON, Del.--(BUSINESS WIRE)--Aug. 30, 2016--
Incyte Corporation (Nasdaq:INCY) announced today that it will present at
the following investor conferences during the month of September:
Morgan Stanley Global Healthcare Conference on Wednesday, September
14, 2016 at 11:05 am (EDT) in New York; and
LEERINK Partners Rare Disease & Immuno-Oncology Roundtable on
Thursday, September 29, 2016 at 3:45 pm (EDT) in N... |
| | | August 25, 2016 | Forbes Magazine Names Incyte to its List of World’s Most Innovative Companies for Second Consecutive Year| Company ranked 4th in 2016 and in Top 10 for
Second Year Running
WILMINGTON, Del.--(BUSINESS WIRE)--Aug. 25, 2016--
Incyte Corporation (Nasdaq:INCY) today announced it has been ranked 4th
on Forbes magazine’s 2016 list of the World’s Most Innovative
Companies. Incyte, a biopharmaceutical company focused on the discovery,
development and commercialization of proprietary therapeutics, is
advancing an innovative and diverse portfolio of large and... |
| | | August 09, 2016 | Incyte Reports 2016 Second-Quarter Financial Results and Updates Key Clinical Programs| $208 million of 2016 second-quarter net product revenues from Jakafi®
(ruxolitinib), representing 46 percent growth over the same period
last year
ECHO-301, the first Phase 3 trial evaluating epacadostat, now
underway in combination with pembrolizumab as first-line treatment of
patients with advanced or metastatic melanoma
New Phase 3 clinical data from COMFORT-I in myelofibrosis and
RESPONSE-2 in poly... |
| | | July 19, 2016 | Updated Data for Epacadostat, Incyte’s Selective IDO1 Inhibitor, Accepted for Presentation at the ESMO Annual Congress 2016| Data from the Phase 1 portion of the ECHO-202 study evaluating
epacadostat in combination with Keytruda®
(pembrolizumab) to be highlighted as a poster discussion
WILMINGTON, Del.--(BUSINESS WIRE)--Jul. 19, 2016--
Incyte Corporation (Nasdaq:INCY) announces that updated data from the
Phase 1 portion of the ECHO-202/KEYNOTE-037 trial has been accepted for
a poster discussion at the European Society for Medical Oncology (ESMO)
Annual Congress 2016... |
| | | July 14, 2016 | Incyte to Report Second Quarter Financial Results| WILMINGTON, Del.--(BUSINESS WIRE)--Jul. 14, 2016--
Incyte Corporation (Nasdaq: INCY) announced today that it has scheduled
its second quarter 2016 financial results conference call and webcast
for 10:00 a.m. ET on Tuesday, August 9, 2016.
The schedule for the press release and conference call/webcast is as
follows:
... |
| | | June 23, 2016 | FDA Grants Breakthrough Therapy Designation for Incyte’s Ruxolitinib (Jakafi®) in Acute Graft-Versus-Host Disease (GVHD)| WILMINGTON, Del.--(BUSINESS WIRE)--Jun. 23, 2016--
Incyte Corporation (Nasdaq: INCY) today announced that the U.S. Food and
Drug Administration (FDA) has granted Breakthrough Therapy Designation
for ruxolitinib (Jakafi®) for the treatment of patients with
acute graft-versus-host disease (GVHD). There are currently no approved
treatments for patients with acute GVHD.
Breakthrough Therapy Designation is designed to expedite the development
a... |
| | | June 22, 2016 | Incyte Announces First Patient Treated in ECHO-301 Phase 3 Study| Pivotal trial to evaluate epacadostat in combination with Keytruda®
(pembrolizumab) as first-line treatment for patients with advanced or
metastatic melanoma
WILMINGTON, Del.--(BUSINESS WIRE)--Jun. 22, 2016--
Incyte Corporation (Nasdaq: INCY) today announced that the first patient
has been treated in the ECHO-301 study—a Phase 3 trial evaluating
epacadostat, Incyte’s investigational, highly potent and selective oral
IDO1 inhibitor, in combinat... |
| | | June 22, 2016 | Agenus Announces Commencement of Phase 1/2 Clinical Trial of anti-GITR Checkpoint Antibody INCAGN1876 in Patients with Solid Tumors| LEXINGTON, Mass.--(BUSINESS WIRE)--Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company developing antibodies including checkpoint inhibitors and other checkpoint modulators, and cancer vaccines, today announced that the first patient has been dosed in a Phase 1/2 clinical trial of the anti-GITR agonist antibody INCAGN1876. The trial is being conducted by, and in collaboration with, Incyte Corporation.The open-label, dose-escalation portion of the trial will evaluate the safety and tolerabilit... |
| | | June 10, 2016 | New Phase 3 Data Show Jakafi® (ruxolitinib) is Superior to Best Available Therapy in Patients with Polycythemia Vera (PV)| 62 percent of PV patients treated with Jakafi achieved hematocrit
control without phlebotomy, compared to 18 percent of patients treated
with best available therapy
RESPONSE-2 data complements previous findings from RESPONSE,
reinforcing Jakafi is effective in PV patients with or without an
enlarged spleen
WILMINGTON, Del.--(BUSINESS WIRE)--Jun. 10, 2016--
Incyte Corporation (Nasdaq: INCY) today announced new ... |
| | | June 09, 2016 | Patient-reported outcomes across phase 3 studies of baricitinib demonstrate statistically significant improvements in physical function and quality of life symptoms in patients with rheumatoid arthritis (RA)| Pivotal trials show treatment with baricitinib resulted in significant improvements in pain, fatigue and ability to perform daily activities compared to methotrexate - the current standard of care - and adalimumab (Humira®)*
INDIANAPOLIS, June 9, 2016 /CNW/ -- Eli Lilly and Company (NYSE: LLY) and Incyte Corporation (NASDAQ: INCY) today announced that in two phase 3 trials patients with rheumatoid arthritis (RA) treated with baricitinib reported significant improvements in quality of life sympt... |
| | | June 09, 2016 | Baricitinib significantly reduces joint damage progression in rheumatoid arthritis in patients who do not respond to conventional DMARDs| Patients from pivotal 24-week phase 3 trial RA-BUILD who entered long-term extension study, RA-BEYOND, demonstrate baricitinib continues to inhibit radiographic progression of structural joint damage over one yearINDIANAPOLIS, June 9, 2016 /CNW/ -- Eli Lilly and Company (NYSE: LLY) and Incyte Corporation (NASDAQ: INCY) today announced that data from a pivotal long-term extension study, RA-BEYOND, was presented at the Annual European Congress of Rheumatology (EULAR 2016) in London. The findings d... |
| | | June 06, 2016 | Five-year Results from Phase 3 Study of Jakafi® (ruxolitinib) Show Sustained Overall Survival Benefit in Patients with Myelofibrosis (MF)| - COMFORT-I data demonstrate that treatment with Jakafi resulted in a
31 percent reduction in the risk of death and sustained durable spleen
volume reduction in patients with MF
- These five-year data support previously published findings for
Jakafi
WILMINGTON, Del.--(BUSINESS WIRE)--Jun. 6, 2016--
Incyte Corporation (Nasdaq:INCY) today announces five-year data from the
Phase 3 COMFORT-I study evaluating the long-term safety and effi... |
| | | June 01, 2016 | Incyte and Moffitt Cancer Center Establish Multi-Year Oncology Research Alliance| Collaboration focuses on basic and translational research involving
novel therapeutic approaches for hematologic malignancies
WILMINGTON, Del. & TAMPA, Fla.--(BUSINESS WIRE)--Jun. 1, 2016--
Incyte Corporation (Nasdaq: INCY) and Moffitt
Cancer Center today announced that they have entered into a research
support and collaboration agreement, whereby Incyte has agreed to
provide funding to conduct three new Moffitt Cancer Center research
prog... |
| | | May 31, 2016 | Incyte Announces the Launch of the Incyte Charitable Giving Foundation| Foundation to Fund Oncology Patient Support and Resources and
Community Partnerships in Delaware
WILMINGTON, Del.--(BUSINESS WIRE)--May 31, 2016--
Incyte Corporation (Nasdaq: INCY), a biopharmaceutical company, today
announced the launch of the Incyte Charitable Giving Foundation, which
will provide charitable donations to publicly-funded 501(c)(3)
tax-exempt nonprofit organizations serving the needs of communities in
Delaware.
... |
| | | May 19, 2016 | Incyte Highlights Jakafi® (ruxolitinib) and Capmatinib Abstracts to be Presented at the 2016 ASCO and EHA Annual Meetings| WILMINGTON, Del.--(BUSINESS WIRE)--May 19, 2016--
Incyte Corporation (Nasdaq: INCY) announces that more than 20 abstracts
featuring its clinical development candidates will be presented at the
2016 American Society of Clinical Oncology (ASCO) and European
Hematology Association (EHA) annual meetings. These conferences will
take place from June 3–7, 2016 (ASCO) in Chicago, Illinois and June
9–12, 2016 (EHA) in Copenhagen, Denmark.
“The abst... |
| | | May 18, 2016 | Incyte to Present at Upcoming Investor Conferences| WILMINGTON, Del.--(BUSINESS WIRE)--May 18, 2016--
Incyte Corporation (Nasdaq:INCY) announced today that it will present at
the following investor conferences during the month of June:
Jefferies 2016 Healthcare Conference on Wednesday, June 8, 2016 at
2:00 pm (EDT) in New York; and
Goldman Sachs 37th Annual Global Healthcare Conference on
Wednesday, June 8, 2016 at 2:00 pm (PDT) / 5:00 pm (EDT) in Rancho
Pa... |
| | | May 09, 2016 | Incyte First Quarter Financial Results Conference Call and Webcast| WILMINGTON, Del.--(BUSINESS WIRE)--May 9, 2016--
Incyte Corporation (Nasdaq: INCY) today confirms the details for its
first quarter 2016 financial results conference call and webcast for
10:00 a.m. ET on Monday, May 9, 2016.
The conference ID number included in this morning’s press releases was
incorrect.
The schedule for the press release and conference call/webcast is as
follows:
... |
| | | May 09, 2016 | Incyte and ARIAD Announce Agreement for Incyte to Acquire ARIAD’s European Operations and In-license Iclusig® (ponatinib) in Europe| Incyte to Accelerate the Expansion of its European Organization to
Optimize the Potential of Future Product Launches in Europe
ARIAD to Receive $140 Million Upfront Payment, Plus Tiered
Royalties on European Sales of Iclusig and Potential Milestones on
Future Indications for Iclusig
WILMINGTON, Del. & CAMBRIDGE, Mass.--(BUSINESS WIRE)--May 9, 2016--
Incyte Corporation (Nasdaq:INCY) and ARIAD Pharmaceuticals... |
| | | May 09, 2016 | Incyte Reports 2016 First-Quarter Financial Results and Updates Shareholders on Key Clinical Programs| $183 million of 2016 first-quarter net product revenues from Jakafi®
(ruxolitinib), representing 59 percent growth over the same period
last year. Full year Jakafi net product revenue guidance increased
from a range of $800-815 million to a range of $815-830 million.
Recent agreements with Lilly and Novartis allow development of
ruxolitinib for the treatment of graft versus host disease (GVHD);
U.S. pivotal trial expected to b... |
| | | April 28, 2016 | Incyte to Present at Upcoming Investor Conferences| WILMINGTON, Del.--(BUSINESS WIRE)--Apr. 28, 2016--
Incyte Corporation (Nasdaq:INCY) announced today that it will present at
the following investor conferences during the month of May:
Bank of America Merrill Lynch 2016 Health Care Conference on
Wednesday, May 11, 2016 at 1:00 pm (PDT) in Las Vegas; and
UBS Global Healthcare Conference on Monday, May 23, 2016 at 1:00 pm
(EDT) in New York
The p... |
| | | April 15, 2016 | Incyte Investor Event at AACR 2016 to Highlight Innovative and Diversified Research and Development Portfolio| Sustained R&D productivity has generated 14 clinical development
candidates against 11 discrete molecular targets
Diverse immuno-oncology and targeted cancer therapy portfolios
comprised of both large and small molecule therapies
Live webcast presentation from AACR taking place Sunday, April 17,
2016 at 7:00 p.m. CDT / 8:00 p.m. EDT
WILMINGTON, Del.--(BUSINESS WIRE)--Apr. 15, 2016--
Incyte ... |
| | | April 14, 2016 | Incyte to Report First Quarter Financial Results| WILMINGTON, Del.--(BUSINESS WIRE)--Apr. 14, 2016--
Incyte Corporation (Nasdaq: INCY) announced today that it has scheduled
its first quarter 2016 financial results conference call and webcast for
10:00 a.m. ET on Monday, May 9, 2016.
The schedule for the press release and conference call/webcast is as
follows:
... |
| | | April 06, 2016 | Incyte Acquires Rights from Lilly to Develop and Commercialize Ruxolitinib (Jakafi®) for the Treatment of Patients with Graft-Versus-Host Disease (GVHD)| Pivotal development program for ruxolitinib in GVHD expected to begin
in 2016
Novartis agreement amended to include development and
commercialization rights for ruxolitinib in GVHD outside of the U.S.
WILMINGTON, Del.--(BUSINESS WIRE)--Apr. 6, 2016--
Incyte Corporation (Nasdaq:INCY) today announced it has acquired the
rights to develop and commercialize ruxolitinib (Jakafi®),
its proprietary JAK1/JAK2 inhibitor, f... |
| | | March 31, 2016 | Phase 3 Study Findings Demonstrate Treatment with Baricitinib Results in Significant Improvements for Patients with Rheumatoid Arthritis Who Had Inadequate Response to Biologics| Pivotal RA-BEACON Study Published in New England Journal of Medicine
INDIANAPOLIS, March 31, 2016 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Incyte Corporation (NASDAQ: INCY) announced that detailed results of RA-BEACON — a pivotal phase 3 global study of baricitinib, a once-daily oral treatment currently under regulatory review for the treatment of moderate-to-severe rheumatoid arthritis (RA) — were published today in the New England Journal of Medicine.
The study met its pr... |
| | | March 16, 2016 | Incyte’s Immuno-oncology and Targeted Therapy Portfolio to be Featured at the AACR Annual Meeting 2016| Ten abstracts selected for presentation from the Company’s GITR
agonist, OX40 agonist, LSD1 inhibitor, BRD (BET) inhibitor, PI3Kδ
inhibitor and JAK1 inhibitor programs
WILMINGTON, Del.--(BUSINESS WIRE)--Mar. 16, 2016--
Incyte Corporation (Nasdaq: INCY) announces that ten abstracts featuring
data from its emerging development portfolio will be presented at the
upcoming American Association for Cancer Research (AACR) Annual Meeting
2016 in New O... |
| | | February 29, 2016 | Incyte Joins Patient Organizations Worldwide in Recognition of Rare Disease Day 2016 to Make Patient Voices Heard| February 29, 2016, commemorates International Rare Disease Day
Incyte Corporation supports efforts to raise awareness and improve
diagnosis and treatment for the nearly 200,000 people in the United
States with MPNs, a group of rare blood cancers
MPN Heroes® 2016 nominations now open for
submission
WILMINGTON, Del.--(BUSINESS WIRE)--Feb. 29, 2016--
Incyte Corporation (Nasdaq: INCY) joins the European Organization for
Rare... |
| | | February 16, 2016 | Incyte to Present at Upcoming Investor Conferences| WILMINGTON, Del.--(BUSINESS WIRE)--Feb. 16, 2016--
Incyte Corporation (Nasdaq:INCY) announced today that it will present at
the following investor conferences during the month of March:
Cowen and Company 36th Annual Health Care Conference on
Monday, March 7, 2016 at 1:20 pm (EST) in Boston; and
Barclays Capital Global Healthcare Conference on Wednesday, March 16,
2016 at 9:30 am (EDT) in Miami
... |
| | | February 11, 2016 | Incyte Reports 2015 Fourth-Quarter and Year-End Financial Results, Provides 2016 Financial Guidance and Updates Shareholders on Key Clinical Programs| $182 million of 2015 fourth-quarter net product revenues from Jakafi®
(ruxolitinib), representing 72 percent growth over the same period
last year and $601 million of 2015 full-year net product revenues from
Jakafi, representing 68 percent growth over last year
2016 guidance for Jakafi net product revenues in the range of $800
million to $815 million, reflecting expectations for continued growth
in underlying demand in myelofi... |
| | | February 11, 2016 | Incyte Announces Decision to Discontinue JANUS Studies of Ruxolitinib plus Capecitabine in Patients with Advanced or Metastatic Pancreatic Cancer| WILMINGTON, Del.--(BUSINESS WIRE)--Feb. 11, 2016--
Incyte Corporation (Nasdaq: INCY) announced today its decision to
discontinue the Phase 3 study (JANUS 1) of ruxolitinib or placebo in
combination with capecitabine for the second-line treatment of patients
with advanced or metastatic pancreatic cancer. The decision to stop the
study was made after a planned interim analysis of JANUS 1 demonstrated
that ruxolitinib plus capecitabine did not show a suffic... |
| | | January 27, 2016 | Incyte Announces Decision to Stop Phase 2 Sub-study of Ruxolitinib Plus Regorafenib in Patients with Metastatic Colorectal Cancer and High CRP| WILMINGTON, Del.--(BUSINESS WIRE)--Jan. 27, 2016--
Incyte Corporation (Nasdaq: INCY) announced today that the Phase 2
sub-study of ruxolitinib or placebo in combination with regorafenib in
patients with relapsed or refractory metastatic colorectal cancer (CRC)
and high C-reactive protein (CRP) will be stopped early. The decision to
stop the sub-study was made after a planned interim analysis of the high
CRP subgroup demonstrated that ruxolitinib plus reg... |
| | | January 21, 2016 | Incyte to Report Fourth Quarter/Year-End Financial Results| WILMINGTON, Del.--(BUSINESS WIRE)--Jan. 21, 2016--
Incyte Corporation (Nasdaq: INCY) announced today that it has scheduled
its fourth quarter 2015 financial results conference call and webcast
for 10:00 a.m. ET on Thursday, February 11, 2016.
The schedule for the press release and conference call/webcast is as
follows:
... |
| | | January 19, 2016 | Lilly and Incyte Announce Submission of New Drug Application to FDA for Oral Once-Daily Baricitinib for Treatment of Moderate-to-Severe Rheumatoid Arthritis| INDIANAPOLIS, Jan. 19, 2016 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and
Incyte Corporation
(NASDAQ: INCY) today announced that Lilly has submitted a new drug application
(NDA) to the U.S. Food and Drug Administration (FDA) for
the approval of oral once-daily baricitinib for the treatment of
moderately-to-severely active rheumatoid arthritis (RA).
As a result, Incyte
will receive a milestone payment of $35 million from Lilly
related to the NDA submission. If baricitinib ... |
| | | January 11, 2016 | Incyte Presents Significant Progress in its Development Portfolio| Rapidly advancing portfolio with 13 development molecules being
investigated as monotherapy and in combination across multiple
indications
Two new development molecules—an LSD1 inhibitor and an anti-GITR
agonist—added to the portfolio and expected to enter the clinic in
first-half of 2016
Rich news flow from pivotal and proof-of-concept programs expected
in 2016
Webcast present... |
| | | January 11, 2016 | Incyte and AstraZeneca Announce New Lung Cancer Clinical Trial Collaboration| WILMINGTON, Del.--(BUSINESS WIRE)--Jan. 11, 2016--
Incyte Corporation (Nasdaq:INCY) and AstraZeneca (NYSE:AZN) today
announced a new collaboration to evaluate the efficacy and safety of
Incyte’s Janus-associated kinase (JAK) 1 inhibitor, INCB39110, in
combination with AstraZeneca’s next generation epidermal growth factor
receptor (EGFR) inhibitor, Tagrisso® (osimertinib). The
combination will be assessed as a second-line treatment for patients
wit... |
| |
|
